Buy Rating Affirmed for Prime Medicine on Strategic Partnerships and Technology Platform Potential
BMO Capital analyst Kostas Biliouris has reiterated their bullish stance on PRME stock, giving a Buy rating yesterday. Kostas Biliouris has ...
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...
24/7 Wall St17h
Got $100? Consider Buying These 2 Penny Stocks in October (PRME, RLX)
You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part ...
Law19h
Bristol Myers Squibb Wins Dismissal of $6.4 Billion Lawsuit Alleging Intentional Delay of Cancer Drug
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...
FiercePharma21h
BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing
For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...
BioSpace22h
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition
District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...
BMS and Prime ink potential $3.5bn deal to develop T cell therapies
As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime ...